Table 1.
Demographics, risk factors and premorbid conditions.
| 2006–2007 | 2008–2009 | 2010–2011 | 2012–2013 | P | |
|---|---|---|---|---|---|
|
| |||||
| Age | |||||
| <40 | 227 (7.7) | 262 (8.6) | 400 (8.5) | 750 (9.5) | .013 |
| 41–<60 | 1692 (57.1) | 1667 (54.5) | 2653 (56.5) | 4416 (55.9) | |
| 61<80 | 978 (33.0) | 1051 (34.3) | 1519 (32.3) | 2569 (32.5) | |
| >80 | 68 (2.3) | 81 (2.6) | 124 (2.6) | 159 (2.0) | |
| Gender | |||||
| Male | 2663 (85.5) | 2731 (85.0) | 4169 (85.3) | 7109 (86.0) | .493 |
| Female | 451 (14.5) | 482 (15.0) | 720 (14.7) | 1158 (14.0) | |
| Ethnicity | |||||
| Malay | 1661 (53.3) | 1786 (55.6) | 2795 (57.2) | 5034 (60.9) | |
| Chinese | 657 (21.1) | 618 (19.2) | 898 (18.4) | 1281 (15.5) | <.001 |
| Indians | 605 (19.4) | 600 (18.7) | 808 (16.5) | 1257 (15.2) | |
| Others | 191 (6.1) | 209 (6.5) | 388 (7.9) | 695 (8.4) | |
| Diabetes mellitus | 1133 (36.4) | 1136 (35.4) | 1816 (37.1) | 2980 (36.0) | <.001 |
| Hypertension | 1517 (48.7) | 1584 (49.3) | 2454 (50.2) | 4151 (50.2) | <.001 |
| Smoking | |||||
| Active/former | 2111 (70.3) | 2087 (68.6) | 3234 (68.6) | 5553 (70.2) | .142 |
| Never | 892 (29.7) | 955(31.4) | 1478 (31.4) | 2359 (29.8) | |
| Dyslipidaema | 656 (21.1) | 851 (26.5) | 1335 (27.3) | 2085 (25.2) | <.001 |
| FHx Premature CAD | 372 (11.9) | 345 (10.7) | 598 (12.2) | 880 (10.6) | <.001 |
| Previous MI | 329 (10.6) | 377 (11.7) | 530 (10.8) | 890 (10.8) | <.001 |
| Chronic Lung Ds | 67 (2.2) | 78 (2.4) | 118 (2.4) | 137 (1.7) | <.001 |
| Cerebrovascular Ds | 95 (3.1) | 72 (2.2) | 120 (2.5) | 227 (2.7) | <.001 |
| Peripheral Vascular Ds | 11 (0.4) | 10 (0.3) | 22 (0.5) | 12 (0.1) | <.001 |
| Chronic Renal Ds | 106 (3.4) | 103 (3.2) | 174 (3.6) | 263 (3.2) | <.001 |
| Killip Class | |||||
| Class I | 1699 (65.9) | 1725 (64.4) | 2643 (64.6) | 4396 (61.3) | |
| Class II | 593 (23.0) | 653 (24.4) | 843 (20.6) | 1452 (20.3) | <.001 |
| Class II | 125 (4.8) | 110 (4.1) | 201 (4.9) | 324 (4.5) | |
| Class IV | 161 (6.2) | 189 (7.1) | 406 (9.9) | 997 (13.9) | |
| Urgent reperfusion therapy | |||||
| Thrombolysis | 2235(74.0) | 2400 (77.6) | 3628 (76.5) | 5712 (70.6) | |
| Primary PCI | 229 (7.6) | 180 (5.8) | 408 (8.6) | 1099 (13.6) | <.001 |
| Not Given (missed/contraindicated/others) | 557 (18.) | 514 (16.7) | 731 (14.9) | 1285(15.6) | |
| Door to needle time (median minutes) | 55 | 48 | 41 | 45 | <.001 |
Data are n (%) unless otherwise noted.